Holen Sie sich die Stockscreener-App
6.89
5.62%
-0.41
Handel nachbörslich:
6.75
-0.14
-2.03%
Schlusskurs vom Vortag:
$7.30
Offen:
$6.87
24-Stunden-Volumen:
3.88M
Relative Volume:
1.21
Marktkapitalisierung:
$713.24M
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-1.2573
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
-17.98%
1M Leistung:
-27.09%
6M Leistung:
-60.96%
1J Leistung:
-72.42%
1-Tages-Spanne:
$6.77
$7.21
1-Wochen-Bereich:
$6.50
$8.43
52-Wochen-Spanne:
$6.50
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
6.89 | 713.24M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
NTLA Investors Have Opportunity to Lead Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
Intellia Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Expands Team: Strategic RSU Grants Worth 8,400 Shares to Attract Top Talent - Stock Titan
Intellia begins phase 3 trial for gene-editing therapy - Investing.com
Intellia Therapeutics Announces First Patient Dosed in the - GlobeNewswire
Revolutionary One-Shot Gene Therapy Enters Final Testing Phase for Fatal Nerve Disease - Stock Titan
Intellia Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 14, 2025 to Discuss Your RightsNTLA - PR Newswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Long Term Trading Analysis for (NTLA) - news.stocktradersdaily.com
ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 9.6%Should You Sell? - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA - GlobeNewswire Inc.
Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy? - Yahoo Finance
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: - GlobeNewswire
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class ActionNTLA - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - StreetInsider
8 Best Gene-Editing Stocks to Buy - Insider Monkey
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
2025-03-31 | Intellia Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationNTLA | NDAQ:NTLA | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire
Intellia Focuses on Pipeline Development Amid Stiff Competition - Yahoo Finance
Contact The Gross Law Firm by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc.(NTLA) - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (NTLA) - Seeking Alpha
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNTLA - Marketscreener.com
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion. - TradingView
Shareholders that Lost Money on Intellia Therapeutics, Inc. (NTLA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class ... - Bluefield Daily Telegraph
Levi & Korsinsky Notifies Shareholders of Intellia - GlobeNewswire
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication - Yahoo Finance
The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025NTLA - PR Newswire
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - TradingView
Intellia Therapeutics, Inc. Shareholders are Reminded of - GlobeNewswire
Intellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLA - TradingView
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of - GlobeNewswire
Intellia stock plunges to 52-week low, hits $8.3 amid biotech rout - Investing.com India
NTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TradingView
Intellia gets FDA RMAT status for Regeneron-partnered gene editing drug - Seeking Alpha
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation - Nasdaq
Intellia Therapeutics Announces FDA Regenerative Medicine - GlobeNewswire
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - The Manila Times
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):